The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
AI-powered cardiometabolic wellness platform for India’s workforce
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Subscribe To Our Newsletter & Stay Updated
